Skip to main content
. 2021 Feb 27;12:2040622320983121. doi: 10.1177/2040622320983121

Table 3.

AEs leading to DMTs discontinuation among the three groups.

Total (n = 62/202) No-poly RRMS (n = 30/62) Minor-poly RRMS (n = 8/62) Major-poly RRMS (n = 24/62)
Flu-like syndrome 14 (22.6) 9 (30) 2 (25) 3 (12.5)
Gastrointestinal side effects 14 (22.6) 7 (23.4) 1 (12.5) 6 (25)
Injection sites reactions 4 (6.5) 2 (6.6) 1 (12.5) 1 (4.2)
Transaminases elevation 9 (14.5) 3 (10) 2 (25) 4 (16.7)
Thrombocytopenia 1 (1.6) 1 (12.5)
Lymphocytopenia 2 (3.2) 1 (12.5) 1 (4.2)
Dysthyroidism 8 (12.9) 5 (16.6) 3 (12.5)
Arrhythmia 1 (1.6) 1 (4.2)
Depression 9 (14.5) 4 (13.4) 5 (20.7)

AE, adverse event; DMT, disease-modifying therapy; RRMS, relapsing–remitting multiple sclerosis.